FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate
about
ZBTB2 increases PDK4 expression by transcriptional repression of RelA/p65Redox biology in pulmonary arterial hypertension (2013 Grover Conference Series)Cellular and molecular basis of RV hypertrophy in congenital heart diseaseCardiac energy metabolic alterations in pressure overload-induced left and right heart failure (2013 Grover Conference Series)Right ventricular adaptation and failure in pulmonary arterial hypertension.Structure-guided Development of Specific Pyruvate Dehydrogenase Kinase Inhibitors Targeting the ATP-binding PocketMolecular Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial HypertensionEmerging concepts in the molecular basis of pulmonary arterial hypertension: part I: metabolic plasticity and mitochondrial dynamics in the pulmonary circulation and right ventricle in pulmonary arterial hypertensionThe right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure.The role of pyruvate dehydrogenase kinase in diabetes and obesity.Up-regulation of hexokinase1 in the right ventricle of monocrotaline induced pulmonary hypertension.Mitochondrial dynamics in pulmonary arterial hypertension.Forkhead box O-1 modulation improves endothelial insulin resistance in human obesity.Right ventricular failure due to chronic pressure load: What have we learned in animal models since the NIH working group statement?Paternal long-term exercise programs offspring for low energy expenditure and increased risk for obesity in mice.Fatty Acid Metabolic Defects and Right Ventricular Lipotoxicity in Human Pulmonary Arterial Hypertension.Intratracheal instillation of ethyl pyruvate nanoparticles prevents the development of shunt-flow-induced pulmonary arterial hypertension in a rat model.Transcription factors, transcriptional coregulators, and epigenetic modulation in the control of pulmonary vascular cell phenotype: therapeutic implications for pulmonary hypertension (2015 Grover Conference series).Platelets from pulmonary hypertension patients show increased mitochondrial reserve capacity.Regulation of pyruvate metabolism in metabolic-related diseases.Fatty acid metabolism in pulmonary arterial hypertension: role in right ventricular dysfunction and hypertrophy.Pyridine Dinucleotides from Molecules to Man.Update on pulmonary arterial hypertension pharmacotherapy.Sex Differences in Metabolic Cardiomyopathy.Involvement of the Warburg effect in non-tumor diseases processes.Pulmonary arterial hypertension - progress in understanding the disease and prioritizing strategies for drug development.Increased Pyruvate Dehydrogenase Kinase 4 Expression in Lung Pericytes Is Associated with Reduced Endothelial-Pericyte Interactions and Small Vessel Loss in Pulmonary Arterial Hypertension.Enhanced pyruvate dehydrogenase activity improves cardiac outcomes in a murine model of cardiac arrest.Update on novel targets and potential treatment avenues in pulmonary hypertension.Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension.Pyruvate Kinase and Warburg Metabolism in Pulmonary Arterial Hypertension: Uncoupled Glycolysis and the Cancer-Like Phenotype of Pulmonary Arterial Hypertension.FoxO1 regulates myocardial glucose oxidation rates via transcriptional control of pyruvate dehydrogenase kinase 4 expression.Development of Dihydroxyphenyl Sulfonylisoindoline Derivatives as Liver-Targeting Pyruvate Dehydrogenase Kinase Inhibitors.Current Knowledge and Recent Advances of Right Ventricular Molecular Biology and Metabolism from Congenital Heart Disease to Chronic Pulmonary Hypertension.Finding a job for dichloroacetate.Reversal of right ventricular remodeling by dichloroacetate is related to inhibition of mitochondria-dependent apoptosis.Effects of an endothelin receptor antagonist, Macitentan, on right ventricular substrate utilization and function in a Sugen 5416/hypoxia rat model of severe pulmonary arterial hypertension.Acetylation contributes to hypertrophy-caused maturational delay of cardiac energy metabolism.Uncoupling of glycolysis from glucose oxidation accompanies the development of heart failure with preserved ejection fraction.Alpha-enolase regulates the malignant phenotype of pulmonary artery smooth muscle cells via the AMPK-Akt pathway
P2860
Q24315863-573D5DA4-F1A9-4DE9-87A1-1B7EA4BFD1A3Q26772286-828B3EDA-81F2-4375-8B3E-F749430575E6Q26777913-36677CA3-E11A-4A88-B76D-E8A723B8D984Q26825047-4856449E-3E33-4A8C-ACF0-E20BFC4DE0DFQ27318422-7557D368-2E21-47B9-A5E8-13EE16A14BDBQ27680986-F49EE574-D91C-4684-B0AA-FA8E03803E0EQ28067063-720EF40A-751A-42A7-B899-19DCB90CA730Q28083183-5D900789-96FF-438A-9A15-30FA1E2CFAC2Q30585014-C4863AE6-DC53-4862-954D-010BF2485142Q33850306-D81BEEAA-AB08-4234-AE84-FD7D1D7A4E2EQ34346381-E5ADBFF1-48B3-49EA-B069-6BA77B9DC282Q35116543-FF2E06C7-DC2D-42CD-B28B-1B643EEE55EFQ35613380-5626FC4C-E0DD-4F73-ADA7-F7C6602B2C8AQ35725663-4FFC8FAF-10A4-455A-B356-437617E4EE7CQ36467016-4BD8F5DE-7A78-40CC-AF11-A1E6D579A60DQ36909329-902BB60C-D39B-452E-BDE2-C6623059770AQ37003895-D79D1147-AD85-4028-BC1F-7FD5D333F05FQ37555457-A7A68DBF-2E0F-44B0-BC0F-072F51F18C8BQ37677425-82A7A296-0D83-4F02-95CD-FAD3FDCD9264Q38161453-9E17E3FB-DA91-48D7-A77E-95ED1C2104BEQ38524717-7D7E24F2-C7FB-4ED1-AAAB-12604CA14C09Q38668667-5E2C6F2A-FB14-4965-8E85-9FB34CB0FC43Q38846020-E4C31DC9-1A03-4544-AB29-1836314C04D2Q39118050-205F3E74-06AD-41D4-A9AA-53EAFBCB27D0Q39295263-AC3380AC-A003-4475-A43E-5B6ADB77C6DAQ39317865-F37A480F-5AA0-4BC5-9395-C72CC249B7AAQ41022731-EE4F7549-F740-40B4-AEF8-DA2A9B327386Q42362104-597786F4-608F-45EB-9D46-4DBE9275F97AQ42784219-C1C213EC-374F-4EC5-99AB-69FCD00FB8FFQ45869636-B0889A96-2443-4599-8F72-8AEC4745FCDFQ47279087-74E58FA5-6D5D-4593-B011-51146B6796FFQ47834016-057C5D1C-B7E8-4CE0-BBCE-8F36E793C618Q48353659-969935A4-F09A-41F4-8792-E07FB7AB6FD6Q52629104-A793D523-A6D7-4044-91A9-A27ED03FEA73Q52885643-41C32CD8-4806-4633-8A91-6DF85286F77FQ53641982-3B583C4A-C3A4-49E8-9810-B6B54C8CA1E0Q53842649-503598C8-9302-42BC-B9DB-AC8719137F4CQ55396281-9B71061C-E86F-4686-8817-DB93CCFC6D59Q55478869-4B248247-905B-4DAA-B1B1-4D1D32477601Q58705752-87B193FC-E4AA-443C-B151-9EA514545F97
P2860
FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
FOXO1-mediated upregulation of ...... ic benefits of dichloroacetate
@ast
FOXO1-mediated upregulation of ...... ic benefits of dichloroacetate
@en
type
label
FOXO1-mediated upregulation of ...... ic benefits of dichloroacetate
@ast
FOXO1-mediated upregulation of ...... ic benefits of dichloroacetate
@en
prefLabel
FOXO1-mediated upregulation of ...... ic benefits of dichloroacetate
@ast
FOXO1-mediated upregulation of ...... ic benefits of dichloroacetate
@en
P2093
P2860
P1476
FOXO1-mediated upregulation of ...... ic benefits of dichloroacetate
@en
P2093
Erik Morrow
Gary D Lopaschuk
John J Ryan
Kishan S Parikh
Peter T Toth
Shelby Kutty
Stephen L Archer
Vaninder K Sidhu
Yong-Hu Fang
P2860
P2888
P304
P356
10.1007/S00109-012-0982-0
P577
2012-12-18T00:00:00Z